Initiator Pharma Q3: Continued efforts in business development - Redeye

Redeye provides a research update following the Q3 report published by Initiator Pharma earlier today. The report did not include any significant surprises as the company continues to operate at a low cash burn, showing promise for the financial runway ahead. With focus on business development efforts, we restate that the full priority for the immediate future will be to find a licensing partner for the candidate. We reiterate our fair value range with a base case valuation of SEK24.

Länk till analysen i sin helhet: https://www.redeye.se/research/1062119/initiator-pharma-q3-continued-efforts-in-business-development?utm_source=finwire&utm_medium=RSS